Peter Zdziarski: Gene Therapy vs Prophylaxis in Glanzmann Thrombasthenia
Peter Zdziarski, Vice President and Marketing Director at the Glanzmann’s Research Foundation, shared a post on LinkedIn:
”Gene Therapy vs Prophylaxis in Glanzmann Thrombasthenia
This is one of the most frequently asked questions I hear from the GT community, and it’s a crucial one.
The distinction matters:
Prophylaxis requires ongoing drug use, often weekly or bi-weekly.
Gene therapy is designed as a single procedure and has the potential for a lasting solution.
What’s important to remember is that both options are still in clinical trials. Marketing to the GT community has put a heavy spotlight on prophylaxis in recent years. For many families, this has made it seem like the only new option, when in fact gene therapy for GT has been in development for years.
That’s why staying informed is so critical. There is meaningful research happening that could change the future of treatment. Both options, and the realities behind them, deserve attention.
If you or a loved one is living with GT, I strongly encourage you to follow the groundbreaking work of Dr. David Wilcox and his team at the Medical College of Wisconsin. Their efforts are bringing real hope for a long-term solution to Glanzmann Thrombasthenia.
Knowledge is power. The more we understand the science, the costs, and the possibilities, the better prepared we are to make the best decisions for our community’s future.”
Find more information here.
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 16, 2026, 15:44Lakmali Silva: Silva Lab Showcases Research at the Gordon Research Conference on Plasminogen and Extracellular Proteolysis
-
Feb 16, 2026, 15:36Heghine Khachatryan: Strengthening Maternal Resilience Against Postpartum Hemorrhage
-
Feb 16, 2026, 15:34Sevak Mirabyan: Advancing Cancer Care Through Knowledge, Collaboration, and Early Diagnosis in Armenia
-
Feb 16, 2026, 15:29Chokri Ben Lamine: Key Clinical Insights of Drug Induced Thrombocytopenia
-
Feb 16, 2026, 15:28Ney Carter Borges: Coronary Intravascular Lithotripsy – Clinical Performance and Safety
-
Feb 16, 2026, 15:24Flora Peyvandi: Highlighting Overdose, Homicide, and Suicide as Causes of Maternal Death in the US
-
Feb 16, 2026, 14:53Wafaa Abougabal: Differential Diagnosis of Acute Neurologic Deficits and Stroke in PICU
-
Feb 16, 2026, 14:49Nayab Ahmed: Synthesis of ATP and Its Significance in Storage of Blood
-
Feb 16, 2026, 14:44Lukasz Kuzma: NOAC Monotherapy vs NOAC Plus Clopidogrel in AF Beyond One Year After DES